M

Mirion Technologies

MIR · NYSE · Industrials

$15.76

$0.47 (-2.96%) today

Loading live data...

Market Cap

$3.92B

24h Volume

$118.2M

P/E Ratio

175.1

52w High

$29.75

52w Low

$14.40

Est. AI Revenue

10%

Loading chart data...

7-Day Sparkline (Static)

Company facts

CEO: Thomas D. Logan
Founded: 2005
HQ: Atlanta, GA
Employees: 3,200

Performance

24 Hours-2.96%
7 Days-1.38%
30 Days+1.03%
1 Year-35.52%

About Mirion Technologies

Mirion Technologies makes radiation detection and measurement equipment. It sells instruments, sensors, software, and services to nuclear power plants, national labs, hospitals, and defense customers, with much of its revenue recurring through dosimetry services, calibration, and replacement cycles. It is one of the largest dedicated suppliers in radiation safety.

Its products span radiation detection and monitoring systems for reactors and fuel facilities, nuclear instrumentation and control equipment, and dosimetry services that track worker radiation exposure. A medical business supplies quality assurance and dosimetry tools for radiation based cancer treatment.

Founded in 2005 and headquartered in Atlanta, Georgia, Mirion employs about 3,200 people and trades on the NYSE. Its installed base spans much of the world's operating nuclear fleet, giving it steady exposure to every reactor that runs, restarts, or gets built.

Mirion Technologies in the AI buildout

Mirion sits in the Power & Energy layer of the AI buildout as a picks-and-shovels supplier to the nuclear revival. AI data centers are pushing utilities and hyperscalers toward nuclear power, which means plant restarts, license extensions, uprates, and new SMR programs. Every one of those projects needs radiation detection, monitoring, and instrumentation, and Mirion already holds supply agreements with SMR developers. Its exposure grows with nuclear construction volume rather than with any single AI contract, so the buildout lifts demand indirectly but broadly.

MIR is tracked in Power & Energy, rated Growing on the AI Exposure leaderboard.

By the numbers

52-week range

MIR trades at $15.76, 9% of the way up its 52-week range of $14.40 to $29.75.

Market cap

Market capitalization is $3.92B, with an AI Exposure Score of 34 out of 100.

Valuation vs peers

Its P/E ratio of 175.1 is above the Power & Energy category median of 30.8.

Next earnings

Mirion Technologies is next expected to report earnings on October 27, 2026.

Market data as of the close on . Prices are end of day, not live.

Frequently asked questions

What does Mirion Technologies do?

Mirion Technologies makes radiation detection, measurement, and monitoring products. Its instruments, software, and dosimetry services are used by nuclear power plants, laboratories, hospitals, defense customers, and industrial sites to detect radiation and keep people and facilities safe.

How is Mirion Technologies exposed to AI?

Supercycle rates it Growing with an AI Exposure Score of 34 out of 100. AI data center electricity demand is driving nuclear restarts, uprates, and SMR programs, and each of those projects needs Mirion's detection and instrumentation gear. Medical and defense revenue dilutes the linkage.

What products does Mirion sell?

Its lines include radiation detection and monitoring systems for reactors and fuel facilities, nuclear instrumentation and control equipment, and dosimetry services that track worker radiation exposure. It also supplies quality assurance and dosimetry tools for radiation based cancer care in hospitals.

Is MIR a pure play AI stock?

No. Supercycle classifies Mirion as Growing. It benefits when AI electricity demand drives nuclear construction, but its revenue comes from radiation safety products across nuclear, medical, defense, and industrial markets, not from AI itself.

Who leads Mirion Technologies?

Thomas Logan serves as chief executive officer and has led the company since its formation in 2005, including through its public listing. Mirion is headquartered in Atlanta, Georgia and employs about 3,200 people worldwide.

Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.

Related reading